Dr. Anahid Jewett

Dr. Anahid Jewett is an internationally recognized expert in tumor immunology, natural killer (NK) cell biology, and cancer immunotherapy. She is the co-founder and Chief Scientific Advisor at NKore Biotherapeutics, where her groundbreaking research focuses on developing innovative NK cell-based therapies to combat cancer.

Dr. Jewett earned her Ph.D. in Epidemiology/Immunology/Pathology from UCLA in 1993. She is a professor and the Director of the Tumor Immunology Laboratory in the Division of Oral Biology and Medicine at UCLA and a faculty member at the Weintraub Center for Reconstructive Biotechnology. She is also affiliated with the Jonsson Comprehensive Cancer Center (JCCC) and UCLA’s Tumor Immunology subgroup.

Dr. Jewett has made significant scientific contributions, including the identification of "split anergy" in NK cells, advancing our understanding of immune system regulation. Her research demonstrated NK cells’ critical role in eliminating and differentiating cancer stem cells, leading to the development of "supercharged" NK cells for immunotherapy. She also created a probiotic formulation to enhance cancer treatment outcomes.

As a prolific researcher, she has authored over 100 high-impact publications and delivered more than 200 lectures worldwide. Her laboratory at UCLA has trained over 150 graduate students and professionals, many of whom now lead programs in immunology and oncology.

Dr. Jewett has collaborated with researchers globally, including those in China, Mexico, and Sweden, and her work is supported by prestigious grants such as those from the NIH. At NKore Biotherapeutics, she is instrumental in advancing NK101, a next-generation therapy that harnesses enhanced NK cells to target cancer stem cells, offering a new frontier in cancer treatment.

Dr. Jewett’s leadership and dedication to advancing immunotherapy and mentoring future leaders make her a trailblazer in the fight against cancer.